Navigation Links
Study Demonstrates a Safe and Cost Effective Source of Recombinant Human Transferrin

Optiferrin, InVitria’s recombinant human transferrin, outperforms iron chelators and provides a cost-effective cell culture media supplement that is consistent and animal component free.

Fort Collins, CO (PRWEB) June 17, 2010 -- A shift in the life science market has begun to steer cell culture scientists to re-evaluate their use of native transferrin and iron chelators to pursue recombinant alternatives. Transferrin regulates the uptake, transport and utilization of iron for cellular function, increasing cell growth and productivity. Native transferrin found in bovine or human serum has been widely used in cell culture for these added benefits. However, regulatory issues continue to arise with the use of native transferrin due to blood-borne pathogens.

A recent study published May 2010 in the Protein Expression and Purification Journal demonstrated that transferrin is efficiently produced using recombinant technology. The study, ‘Expression, Purification and Characterization of Recombinant Human Transferrin from Rice’ concluded that recombinant human transferrin can be expressed at very high levels of 10 grams per kilogram of biomass. These results were accomplished by utilizing the unique and proprietary expression system known as ExpressTec.

“Using the ExpressTec system for animal component free production of recombinant proteins has proven to not only provide safety and regulatory advantages, but also allows cost-effective sources of recombinant proteins like transferrin,” said Ning Huang, Vice President of Research and Development at InVitria.

Rice-derived recombinant human transferrin, tradename OptiferrinTM, is structurally and functionally similar to native transferrin. The results of this study show that effective and efficient methods of producing recombinant proteins enable products like Optiferrin to be cost effective and safe when compared to animal-derived transferrin.

“In this paper, we describe the unrivaled efficiency that we have achieved in a plant-based production system. These expression yields are significantly higher than other systems, which is critical to achieving commercially attractive products like Optiferrin, recombinant human transferrin,” said Deshui Zhang, InVitria Scientist and Lead Author.

InVitria has utilized Optiferrin to develop cell culture media supplements that avoid concerns about blood-borne pathogens found in animal or human serum while still optimizing performance in cell culture. Optiferrin eliminates the nuisances of serum contamination and iron chelators in mammalian cell culture by providing a well defined, high performance and animal-free solution.

“Transferrin delivers necessary iron to cells, maintains iron balance, and avoids the toxic effects of iron compounds. Optiferrin outperforms iron chelators and provides a cost effective alternative to animal-derived transferrin,” said Dr. Steve Pettit, Director of Cell Culture Research and Development at InVitria.

Optiferrin is suitable for all applications in mammalian cell culture, stem cells, regenerative medicine and biopharmaceutical drug delivery. To learn more about Optiferrin and to purchase online please visit

About InVitria –
InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media supplements and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

For more information about InVitria’s products, please e-mail info(at)InVitria(dot)com.

All InVitria products can be purchased online at or by calling 1-800-916-8311.


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Antiretrovirals During Breast-Feeding Shield Babies From HIV, Study Shows
2. Sex, drugs and moral goals: Penn study of reproductive strategies and recreational drug use
3. Twin study shows Mediterranean-style diet improves heart function
4. Study examines reasons patients with early stage lung cancer do not have surgery
5. UNC study helps explain why black patients with lung cancer have surgery less often than whites
6. Females May Be Naturally More Prone to Stress: Animal Study
7. Mastectomy Rates Down Overall, New Study Finds
8. Study: Getting patients to take their asthma meds
9. Study Probes Causes of Anger in Returning U.S. Soldiers
10. Study: Specific PTSD symptoms related to anger and aggressiveness among Iraq/Afghanistan veterans
11. Study: Adults take their physical activity on the road
Post Your Comments:
Related Image:
Study Demonstrates a Safe and Cost Effective Source of Recombinant Human Transferrin 
(Date:11/26/2015)... ... ... Jobs in hospital medical laboratories and in the imaging field lead the many ... Medical Group . These fields, as well as travel nursing, ranked at ... through the company’s website, , The leading healthcare staffing agency released ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... Indosoft Inc., ... inclusion of an application server to improve system efficiency and reliability. , The new ... many of these standards, the system avoids locking itself into a specific piece of ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... recognized once again for its stellar workplace culture with the company’s Cincinnati office ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s ...
(Date:11/25/2015)... Friendswood, TX (PRWEB) , ... November 25, 2015 , ... ... through the companies’ “ Two Organizations, One Beat ” campaign. The partnership between the ... its services to aid in MAP International’s cause. , MAP International was founded in ...
(Date:11/25/2015)... Raton, Florida (PRWEB) , ... November 25, 2015 ... ... diagnostic testing for physicians and athletic programs, launches new Wimbledon Athletics ... importance of testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26 november 2015 AAIPharma Services ... geplande investering aan van ten minste $15,8 ... en het mondiale hoofdkantoor in ... resulteren in extra kantoorruimte en extra capaciteit ... groeiende behoeften van de farmaceutische en biotechnologische ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and Markets ( ... Pacific Cardiac Pacemaker Market Outlook to 2019 - Rise in ... Demand " report to their offering. ... Boston scientific and others. ... including Medtronic, Biotronik, Boston scientific and ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology: